Currently, the cGAS-STING pathway has demonstrated great potential in overcoming drug resistance and enhancing anti-tumor immunity, which can be activated by STING agonists or drugs related to the activation pathway, thus playing an important role in immunotherapy. This evidence concerns the gene STING1 and neoplasm.